ClinVar Miner

Submissions for variant NM_014334.4(FRRS1L):c.692G>A (p.Trp231Ter)

dbSNP: rs878853281
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Labcorp Genetics (formerly Invitae), Labcorp RCV000225178 SCV000817715 pathogenic Developmental and epileptic encephalopathy, 37 2022-01-18 criteria provided, single submitter clinical testing ClinVar contains an entry for this variant (Variation ID: 218152). This premature translational stop signal has been observed in individual(s) with early infantile epileptic encephalopathy (PMID: 27236917; Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. This variant is present in population databases (no rsID available, gnomAD 0.0009%). This sequence change creates a premature translational stop signal (p.Trp282*) in the FRRS1L gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 63 amino acid(s) of the FRRS1L protein. Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. For these reasons, this variant has been classified as Pathogenic. This variant disrupts a region of the FRRS1L protein in which other variant(s) (p.Arg292*, p.Gln321*) have been determined to be pathogenic (PMID: 27236917; Invitae). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. Experimental studies have shown that this premature translational stop signal affects FRRS1L function (PMID: 27236917).
Kruer lab, Phoenix Children's Hospital RCV000239392 SCV000257327 pathogenic Seizure; Chorea; Progressive encephalopathy 2015-11-11 no assertion criteria provided research Leads to loss of protein by immunoblot; leads to impaired co-localization with GluR1 component of AMPA receptor by TIRF; loss of FRRS1L leads to attenuated AMPA currents by electrophysiology
OMIM RCV000225178 SCV000282228 pathogenic Developmental and epileptic encephalopathy, 37 2020-10-23 no assertion criteria provided literature only

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.